Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Jesse Schulman who wrote (1081)	3/7/2000 9:08:00 AM
From: yosi s	Read Replies (1) \| Respond to of 1386

As for mortality results in phase 2. If you put 1+1. look what you get. 1.Phase 2 cohort 2 showed statistical significance in reduction of Intra Cranial pressure. 2. A + statistical result in a small number of patient is just as good as in large number. (that is the idea to limit the size to get to a valid result.) 3.Marshal's study, as published in a landmark article,this Jan 2000, Showed that mortality is 50% in those patients that see their intracranial pressure raising . 4. By adding those studies you got a great winner. Prevent raise in intra craial pressure =prevents mortality.